Has the DAPT-MVD trial changed your approach to DAPT duration in an event-free patient with multivessel coronary artery disease at 12 months, given the broader trend toward de-escalation in contemporary practice?

DAPT-MVD selected a "high ischemic, low bleeding risk" population of Chinese patients under 75, mostly ACS, who had already tolerated 1 year of DAPT in a single Asian country, and randomized DAPT versus aspirin. The DAPT-MVD trial showed that extended DAPT versus aspirin alone reduced the composite ...